Clinical research progress of palbociclib in treatment of breast cancer

Author: Zhi WANG ¹ ; Xin ZHOU ¹ ; Xueru HE ¹ ; Yuhao FU ¹ ; Xuejiao XUN ¹ ; Zhi WANG ² ; Xin ZHOU ² ; Xueru HE ² ; Yuhao FU ² ; Xuejiao XUN ² ; Ying LI ² ; Zhanjun DONG ²
Author Information

1. Graduate School of Hebei Medical University
2. Hebei General Hospital
Publication Type:Journal Article
Keywords: breast cancer; clinical trials; palbociclib; side effect
From: Chinese Journal of Clinical Pharmacology and Therapeutics 2023;28(2):205-213
CountryChina
Language:Chinese
Abstract: Palbocicril, the first cyclin-dependent kinases 4 and 6 inhibitors, is a crucial milestone in the development history of antineoplastic drugs. It combined with aromatase inhibitor or fulvestrant as first-line, second-line or post-line therapy has good efficacy and safety for hormone receptor-positive, human epidermal growth factor receptor-2 negative locally advanced or metastatic breast cancer, which has a good application prospect. This article summarizes the clinical trials and safety studies related to palbociclib.